Denver, Sept. 25, 2013 (GLOBE NEWSWIRE) -- September 25, 2013 - FusionPharm, Inc, FSPM (www.fusionpharminc.com), the Denver based manufacturer of the PharmPods™ cultivation system (www.pharmpods.com) today announced that it has secured a new manufacturing and sales center facility in the Denver area. The new facility, which will house executive offices, a sales center complete with demo containers and approximately 6,000 square feet of manufacturing, will allow the company to grow with it's ever expanding marketplace.
"The new sales center will greatly enhance our sales staff's ability to show our product variety and capabilities and we expect our sales to see significant increases in the next 6 months", commented FusionPharm CEO Scott Dittman. "We were absolutely bursting at the seams in our existing facility. The new facility will not only improve our productivity and efficiency, but will allow us to keep up with our pending sales pipeline" concluded Mr. Dittman.
About FusionPharm Inc. (FSPM)
FusionPharm, Inc. (FSPM) (www.fusionpharminc.com) was organized to capitalize on opportunities present in the rapidly growing vertical farming and cannabis industries. FusionPharm's primary focus is the development and deployment of the patent pending PharmPods™ advanced hydroponic commercial cultivation systems. PharmPods are constructed from standard ISO steel shipping containers that are repurposed for use in indoor controlled environment agriculture. Modular, stackable, cost competitive and financeable, PharmPods have become the industry leader for professional, commercial scale indoor plant cultivation.
NOTES ABOUT FORWARD-LOOKING STATEMENTS: Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company's Securities and Exchange Commission reports and filings. Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.
CONTACT: email@example.com Source:FusionPharm, Inc.